PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2025. Verfasst von Ambati Himaja und 5 weiteren Autor:innen. Beteiligte Einrichtung: Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500…. Hauptthemen laut MEDLINE: Histone Deacetylases, Histone Deacetylase Inhibitors, Epigenesis, Genetic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: DHR-Indian Council of Medical Research.
Abstract (Originalsprache)
Proteolysis‐targeting chimeras (PROTACs) have emerged as an excellent strategy for targeted protein degradation by the ubiquitin‐proteasome system. Traditional inhibitors suppress the enzymatic activity, but the PROTACs utilize the method of total degradation of protein, promising prolonged and target‐specific therapeutic efficacy. Histone deacetylases (HDACs) are epigenetic regulators, implicated in most cancers, neurodegeneration, and other inflammatory diseases. Therefore, HDAC‐PROTAC development provides a unique approach to overcome the limitations of conventional HDAC inhibitors, including off‐target effects, short duration of action, and resistance mechanisms. Recent advancements in HDAC‐PROTACs lead to the design of selective degraders for specific isoforms of HDACs, including HDAC3, HDAC4, HDAC6, and HDAC8, representing superior efficacy in preclinical studies. This review highlights the progress of HDAC‐targeting PROTACs, focusing on structural optimization, selectivity enhancements, and therapeutic applications with their degradation potential. However, various challenges include poor pharmacokinetics and bioavailability, and limited in vivo validation for further safety, efficacy analysis. Further research and optimization efforts will be pivotal in translating HDAC‐PROTACs into clinically viable therapies for cancer and other epigenetic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
- Computer Aided Drug Design (CADD) Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, 700032, India.
- School of Pharmacy, The Neotia University, Sarisa, Diamond Harbour Road, 24 Parganas (South), Sarisa, West Bengal, 743368, India.
- Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
ORCID-Profile: Ambati Himaja, Debojyoti Halder, Suvankar Banerjee, Swati Biswas, Nilanjan Adhikari, Balaram Ghosh
Förderung
- DHR-Indian Council of Medical Research
Zitieren
APA
Himaja, A., Halder, D., Banerjee, S., Biswas, S., Adhikari, N., & Ghosh, B. (2025). PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies. ChemMedChem. https://doi.org/10.1002/cmdc.202500203
Vancouver
Himaja A, Halder D, Banerjee S, Biswas S, Adhikari N, Ghosh B. PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies. ChemMedChem. 2025. doi:10.1002/cmdc.202500203
BibTeX
@article{Himaja2025,
author = {Himaja, Ambati and Halder, Debojyoti and Banerjee, Suvankar and Biswas, Swati and Adhikari, Nilanjan and Ghosh, Balaram},
title = {PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500203}
}
EUVIMED